Midazolam /kg
Phase 2Small molecule
Midazolam /kg is one of 46 small molecule programs targeting Post Operative Nausea and Vomiting. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
45 competitors in Strabismus
#DrugCompanyPhaseTrials
1Versed
CConrado Roberto Hoffmann Filho
Approved
Botox
RRevance Therapeutics, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Aloxi
AAvyxa
Approved
Decadron
AAspen Global Incorporated
Approved
Botulinum Toxin a
GSKPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
GSK1358820
GSKPhase 3
Tylenol
MMetroHealth Medical Center
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Strabismus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Midazolam /kg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKorea University Anam Hospital